Skip to content
Screener

Solid Biosciences Inc. SLDB Q2 2025 earnings

Reported August 12, 2025 · Before market open

EPS-$0.42Beat by $0.09
EPS estimate-$0.51

Next report

Nov 2, 2026 (in a month)
EPS estimate-$0.37

Financials

Q2 2025

Income statement

See full
Operating income-$41.7M-50.0%
Net income-$39.5M-57.5%
EPS (diluted)-$0.42+31.1%

Balance sheet

See full
Cash & equivalents$138.9M+44.9%
Total debt$23.1M-8.9%
Total equity$258.3M+33.7%
Total assets$308.3M+33.5%

Cash flow

See full
Operating cash flow-$37.4M-74.3%
CapEx$377.0K+31.8%
Free cash flow-$37.8M-73.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$376.34M+72.9%
Enterprise value$260.46M+77.1%

Returns & leverage

See full
Return on equity-68.2%+35.7pp
Debt / equity0.1×0.0×
Current ratio9.3×-4.1×

FAQ

When did Solid Biosciences Inc. report Q2 2025 earnings?
Solid Biosciences Inc. (SLDB) reported Q2 2025 earnings on August 12, 2025 before market open.
What were Solid Biosciences Inc.'s Q2 2025 revenue and EPS?
Solid Biosciences Inc. reported eps of $-0.42 for Q2 2025.
Did Solid Biosciences Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.51 by $0.09.
How did Solid Biosciences Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 31.1% from $-0.61.
Where can I find Solid Biosciences Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-107279) directly on SEC EDGAR. The filing index links above go to sec.gov.